Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel Sells 9,000 Shares

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 9,000 shares of the stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $127.13, for a total value of $1,144,170.00. Following the completion of the sale, the chief executive officer now owns 5,395,535 shares in the company, valued at approximately $685,934,364.55. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Stephane Bancel also recently made the following trade(s):

  • On Wednesday, April 27th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $142.14, for a total value of $1,279,260.00.
  • On Wednesday, April 20th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $150.59, for a total value of $1,355,310.00.
  • On Wednesday, April 13th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $170.26, for a total value of $1,532,340.00.
  • On Wednesday, April 6th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $158.70, for a total value of $1,428,300.00.
  • On Wednesday, March 30th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $176.83, for a total value of $1,591,470.00.
  • On Wednesday, March 23rd, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $180.15, for a total value of $1,621,350.00.
  • On Wednesday, March 16th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $161.63, for a total value of $1,454,670.00.
  • On Wednesday, February 23rd, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $144.60, for a total value of $1,301,400.00.
  • On Wednesday, February 16th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $147.80, for a total value of $1,330,200.00.

Moderna stock opened at $137.91 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.56 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $54.86 billion, a PE ratio of 4.05, a P/E/G ratio of 0.70 and a beta of 1.70. Moderna, Inc. has a 12 month low of $119.01 and a 12 month high of $497.49. The stock has a 50-day moving average price of $155.48 and a two-hundred day moving average price of $201.21.

Moderna (NASDAQ:MRNAGet Rating) last posted its earnings results on Wednesday, May 4th. The company reported $8.58 EPS for the quarter, beating the consensus estimate of $6.16 by $2.42. The firm had revenue of $6.07 billion during the quarter, compared to the consensus estimate of $4.43 billion. Moderna had a return on equity of 121.86% and a net margin of 64.77%. The business’s quarterly revenue was up 213.2% on a year-over-year basis. During the same period last year, the company earned $2.84 earnings per share. As a group, analysts predict that Moderna, Inc. will post 27.22 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. raised its position in shares of Moderna by 8.4% during the fourth quarter. Baillie Gifford & Co. now owns 45,772,079 shares of the company’s stock worth $11,625,193,000 after acquiring an additional 3,554,725 shares during the last quarter. BlackRock Inc. raised its position in shares of Moderna by 3.7% during the first quarter. BlackRock Inc. now owns 28,671,935 shares of the company’s stock worth $4,939,029,000 after acquiring an additional 1,010,462 shares during the last quarter. State Street Corp raised its position in shares of Moderna by 6.5% during the fourth quarter. State Street Corp now owns 14,863,370 shares of the company’s stock worth $3,774,999,000 after acquiring an additional 905,789 shares during the last quarter. Theleme Partners LLP raised its position in shares of Moderna by 26.2% during the first quarter. Theleme Partners LLP now owns 6,336,940 shares of the company’s stock worth $1,091,601,000 after acquiring an additional 1,314,766 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Moderna by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 6,032,463 shares of the company’s stock worth $1,527,786,000 after acquiring an additional 272,502 shares during the last quarter. Hedge funds and other institutional investors own 61.20% of the company’s stock.

MRNA has been the topic of several analyst reports. SVB Leerink reduced their target price on Moderna from $81.00 to $80.00 and set an “underperform” rating on the stock in a report on Friday, March 25th. Barclays reduced their target price on Moderna from $404.00 to $210.00 in a report on Friday, February 25th. UBS Group initiated coverage on Moderna in a report on Friday, January 21st. They set a “neutral” rating and a $221.00 target price on the stock. Jefferies Financial Group reduced their target price on Moderna from $200.00 to $170.00 in a report on Friday, February 25th. Finally, Bank of America raised Moderna from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $135.00 to $180.00 in a report on Friday, January 21st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus price target of $246.92.

About Moderna (Get Rating)

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.

See Also

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Want More Great Investing Ideas?

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.